Abbott Soars 9% To Hit Record High Following Q3FY24 Earnings; Profit Surges 26% YoY

Abbott India Ltd witnessed a meteoric rise in its share prices, soaring over 9% to reach an all-time high on Friday, February 2. The surge was triggered by the pharmaceutical company's robust financial performance in the December quarter, highlighted by a 26% year-on-year (YoY) growth in net profit, totalling Rs 311 crore.

The day commenced on a positive note for Abbott India as its stocks opened higher at Rs 26,498.65 per share on the Bombay Stock Exchange (BSE), reflecting a 2.24% uptick from the previous closing figure. The positive momentum persisted, propelling the stock to hit its 52-week pinnacle at Rs 28,286.55 per share during morning trade.

Abbott India's impressive upward trajectory doesn't end there; the pharmaceutical giant has experienced an impressive 42% gain from its 52-week low of Rs 19,900, registered on February 1, 2023.

Market experts are attributing the surge in Abbott India's share price to the company's outstanding growth in revenue and net profit during the December quarter. The pharmaceutical player announced its quarterly earnings report on February 1, after market hours, leaving investors pleasantly surprised.

Abbott India's net profit for Q3 witnessed a substantial YoY surge, reaching Rs 311 crore, up from Rs 246.8 crore during the same period the previous year. Meanwhile, the company's revenue from operations demonstrated a robust uptick of nearly 9%, totalling Rs 1,437 crore in comparison to Rs 1,322.2 crore during the corresponding period of the previous fiscal year.

The company's earnings before interest, tax, depreciation, and amortization (EBITDA) margin stood at 27% for the reporting quarter. This marks a significant improvement from the 23.6% EBITDA margin reported in the third quarter of the fiscal year 2022-23.

As of 2:20 pm on the National Stock Exchange (NSE), Abbott India's shares were trading with gains of more than 8%, reaching Rs 28,000 per share. The pharmaceutical giant has witnessed an ascent of nearly 25% in the last one year.

Investors and industry analysts are optimistic about Abbott India's future prospects, especially considering its robust performance during a challenging economic environment. The pharmaceutical company's strategic initiatives, coupled with its steadfast commitment to innovation and quality, seem to be paying off, garnering the confidence of both existing and potential investors.

Abbott India's Q3 performance has set the stage for a positive trajectory, reaffirming its position as a key player in the pharmaceutical industry. As the market continues to react favourably to the company's financial prowess, all eyes are on Abbott India to see how it will capitalize on this momentum in the coming quarters.